Creld2 function during unfolded protein response is essential for liver

metabolism homeostasis

Paul Kern[1,5], Nora R. Balzer[1], Franziska Bender[5], Alex Frolov[1], Jan-Peter Sowa[6,7],

Lorenzo Bonaguro[2,5], Thomas Ulas[2,4], Christoph Thiele[3], Joachim L. Schultze[2,4], Ali

Canbay[6,7], Reinhard Bauer[5], Elvira Mass[1]*

1 Developmental Biology of the Immune System, Life & Medical Sciences (LIMES)

Institute, University of Bonn, 53115 Bonn, Germany

2 Genomics and Immunoregulation, Life & Medical Sciences (LIMES) Institute,

University of Bonn, 53115 Bonn, Germany

3 Biochemistry & Cell Biology of Lipids, Life & Medical Sciences (LIMES) Institute,

University of Bonn, 53115 Bonn, Germany

4 Platform for Single Cell Genomics and Epigenomics at the German Center for

Neurodegenerative Diseases and the University of Bonn, 53127 Bonn, Germany

5 Developmental Genetics & Molecular Physiology, Life & Medical Sciences (LIMES)

Institute, University of Bonn, 53115 Bonn, Germany

6 Department of Gastroenterology, Hepatology and Infectious Diseases, University

Hospital Magdeburg, 39120 Magdeburg, Germany

7 Department of Medicine, Ruhr University Bochum, University Hospital

Knappschaftskrankenhaus Bochum, 44892 Bochum, Germany

*corresponding author: emass@uni-bonn.de

Abstract

The unfolded protein response (UPR) is associated with the hepatic metabolic function,

yet it is not well understood how endoplasmic reticulum (ER) disturbance might

influence metabolic homeostasis. Here, we describe the physiological function of

Cysteine-rich with EGF-like domains 2 (Creld2), previously characterized as a

downstream target of the ER-stress signal transducer Atf6. Creld2 enhances protein

folding and degradation through its interaction with proteins involved in UPR, thereby,

promoting tolerance of chronic stress and recovery from acute stress. *Creld2-*

deficiency leads to a dysregulated UPR, and causes the development of hepatic

steatosis in male mice, while females are protected. We observed this sex dimorphism

also in humans with fatty liver disease, with only males showing an accumulation of

CRELD2 protein in the liver. These results reveal a Creld2 function at the intersection

between UPR and metabolic homeostasis and suggest a mechanism in which chronic

ER stress underlies fatty liver disease in males.

Introduction

The Cysteine-rich with EGF-like domains (Creld) protein family consists of two

members – Creld1 and Creld2 – and is highly conserved across species [1,2]. The

domain structure between these proteins is almost identical with the only difference of

transmembrane domains being present in Creld1, but lacking in Creld2 [3]. This leads

to the distinct localization and functions of these proteins within a cell: Creld1 is

proposed to be anchored in the endoplasmic reticulum (ER) membrane with its

domains facing the cytoplasm [4], although a plasma membrane bound form facing the

extracellular matrix has been predicted as well [1]. We previously characterized the

function of Creld1 being essential for heart development in mice [4]. Creld2 is localized

predominantly within the ER, can be secreted [3], and has been characterized as a

marker for kidney disease in urine [5] and for prosthetic joint infections in synovial fluid

[6]. However, the physiological role of Creld2 *in vivo* remains unknown.

Several *in vitro* studies have identified Creld2 as an ER-stress inducible gene,

whose expression is regulated by activating transcription factor 6 (Atf6) [7,8]. ER stress

is characterized by an accumulation of proteins in the ER lumen. Consequently, cells

activate an unfolded protein response (UPR), a signaling network that collectively aims

at decreasing ER protein load by broad inhibition of protein synthesis and at the same

time promotes the activation and production of proteins that increase protein folding

capacity and degradation. The latter include chaperones, shuttling proteins that

promote secretion of proteins out of the ER and ER-associated protein degradation

(ERAD) components [9].

The UPR is controlled by three sensors: Atf6, inositol requiring enzyme 1 (Ire1),

and protein kinase RNA-activated (PKR)-like ER kinase (Perk). The ER luminal

domains of the ER stress sensors are bound and thereby inactivated by the chaperone

Grp78 (glucose-regulated protein 78, also known as heat shock protein A5 (Hspa5)).

Upon ER stress Grp78 is sequestered by the accumulation of proteins in the ER lumen,

causing the activation of the three sensors. Perk dimerizes and is activated by trans-

autophosphorylation of its kinase domains, leading to translational inhibition through

eIF2a phosphorylation. This directly enhances the translation of DNA-damage-

inducible 34 (Gadd34) and CAAT/enhancer-binding protein (C/EBP) homologous

protein (Chop). While Gadd34 serves as a feedback loop to dephosphorylate eIF2α

allowing the cell to recover from translational inhibition, increased Chop expression

may trigger cell death due to unresolved ER stress. The kinase Ire1 undergoes

autophosphorylation resulting in splicing of the *X-box binding protein 1* (*sXbp1*) mRNA

producing an active transcription factor, which induces the transcription of chaperones

and ERAD pathway components. ER-membrane bound Atf6 is cleaved and

translocates to the nucleus where it activates target genes including ERAD

components, chaperones, and phospholipid synthesis [10].

The liver is a highly secretory organ and serves frequently as the tissue to study

ER stress. Using genetic and dietary models of obesity, a link between hepatic stress

and insulin resistance has been established [11-14], suggesting that the accumulation of

lipids within hepatocytes and the resulting hepatocellular damage is linked to

dysfunction of the ER. On the contrary, chemically induced UPR leads to hepatic

steatosis through the direct and indirect regulation of lipid metabolism [15-17], leaving the

arrow of causality between hepatosteatosis and UPR unclear.

Here, we generated a *Creld2* knockout mouse to address Creld2 protein

function during steady state, and dissect its role during UPR and diet-induced obesity

in the liver. We show that *Creld2* deficiency promotes the development of liver

steatosis in male mice, and identify Creld2 interaction partners that are involved in ER-

stress release, thereby placing Creld2 functionally into the cellular stress response of

a cell *in vivo*. The conserved function of Creld2 across species is supported by the

accumulation of CRELD2 in male patients with non-alcoholic steatohepatitis (NASH).

Results

<u>Aged *Creld2^eGFP/eGFP* males develop hepatic steatosis</u>

To investigate Creld2 function *in vivo* we generated a *Creld2*-knockout mouse model

by replacing the endogenous locus with an enhanced green fluorescent protein (eGFP)

(*Creld2^eGFP/eGFP*, Figure S1A), allowing the use of both *Creld2^WT/eGFP* *and*

Creld2^eGFP/eGFP as reporter mice for *Creld2* expression. We confirmed ubiquitous

protein expression [18] as well as lack of Creld2 expression in *Creld2^eGFP/eGFP* mice in

various tissues via Western blot (Figure S1B). *Creld2^eGFP/eGFP* mice were born in

Mendelian ratios (Figure 1A) and were viable. Young mice (1-2 month-old) did not

show any differences in body weight (Figure 1B), organ development or changes in

tissue morphology as assessed histologically in the liver, pancreas, and muscle (Figure

S1C, and not shown).

108   We next assessed body and organ weights of ~1-year-old mice (12-15 months).

We observed that the body and liver weight of *Creld2$^{eGFP/eGFP}$* mice was lower than that

of *Creld2$^{WT/WT}$* controls (Figure 1B, C). We first performed hematoxylin/eosin (HE) and

Masson Goldner Trichrome (MGT) stainings to investigate pathophysiological changes

in the liver. While MGT staining did not reveal a fibrotic phenotype (Figure S1D-E),

Creld2$^{eGFP/eGFP}$ animals presented with dilated sinusoids and abundant vacuoles in

hepatocytes indicating a metabolic dysregulation of the liver (Figure 1D). To investigate

whether *Creld2$^{eGFP/eGFP}$* livers store increased amounts of glycogen or lipids, we

performed Periodic Acid-Schiff (PAS) and Oil-red-O (ORO) stainings, respectively. The

glycogen content was not altered (Figure S1D, E), but ORO staining indicated that

Creld2$^{eGFP/eGFP}$ livers contain more neutral lipids compared to *Creld2$^{WT/WT}$* controls

(Figure 1D). Glutamine synthetase (GS) expression in liver parenchyma is typically

restricted to pericentral hepatocytes, however, under high-fat diet conditions GS

expression is upregulated and can be found outside hepatocytes lining the central

veins [19]. Therefore, we assessed GS expression as an indicator of dysregulated

metabolism. Indeed, *Creld2$^{eGFP/eGFP}$* livers showed ectopic expression of GS, while

control livers showed immunoreactivity only in pericentral hepatocytes, as expected

(Figure 1D).

126   To analyse the hepatic neutral lipid composition quantitatively, we performed

thin layer chromatography and observed that *Creld2$^{eGFP/eGFP}$* livers accumulate more

free fatty acids (FFA), diacylglycerols (DAG), cholesterol, and cholesteryl esters,

whereas triacylglycerols (TAG) remain at similar levels as in *Creld2$^{WT/WT}$* livers (Figure

1E). Intriguingly, we noticed that liver pathology was absent in 1-year-old females (not

shown) and lipid content analysis confirmed that *Creld2^eGFP/eGFP* females were

protected from the development of a hepatosteatotic phenotype (Figure 1E).

Our finding that old *Creld2^eGFP/eGFP* males developed hepatosteatosis prompted

us to perform glucose and insulin tolerance tests to assess their glucose homeostasis.

Injection of glucose tendentially led to an augmented blood glucose level response in

Creld2^eGFP/eGFP males after 15-30 minutes when compared to control littermates

(Figure 1F). Correspondingly, *Creld2^eGFP/eGFP* mice were unable to respond as well as

Creld2^WT/WT mice to an injection of insulin, with a maximum drop of blood glucose levels

to ~80 %, while wildtype controls reduced their blood glucose to ~60 % of the starting

value (Figure 1G).

Increased blood glucose concentrations after insulin and glucose injection as

well as abundant DAG levels are indicative for hepatic insulin resistance caused by

impaired insulin signalling at the level of the insulin receptor kinase [20,21]. To investigate

whether *Creld2^eGFP/eGFP* mice suffer from hepatic insulin resistance, we analysed livers

for phosphorylation of Akt as a proxy for active insulin signalling. Yet, *Creld2^eGFP/eGFP*

livers displayed rather elevated pAkt/Akt ratios 15 min after insulin injection in

comparison to *Creld2^WT/WT* mice (Figure 1H), indicating an intact hepatic insulin

receptor signalling. In summary, our data suggest that *Creld2* deficiency causes

hepatic steatosis during ageing in male mice without driving hepatic insulin resistance

or overall obesity.

Aged *Creld2^eGFP/eGFP* males downregulate key mediators of lipid homeostasis in the

liver but show no acute ER stress or inflammatory response

To investigate the underlying molecular mechanisms leading to lipid accumulation in

Creld2^eGFP/eGFP livers, we performed qRT-PCR analyses on key mediators of lipid

homeostasis. We observed that genes encoding the transcription factor *Pgc1α*

(*Ppargc1a*), components of fatty acid oxidation (*Acox1*), acylglycerol metabolism

(*Apoc2, Dgat1, Dgat2*) and cholesterol storage (*Apob100, Lsr*) were downregulated in

livers of *Creld2eGFP/eGFP* males compared to controls (Figure 2A, Table S1).

We next assessed whether *Creld2eGFP/eGFP* livers experience increased ER

stress due to the accumulation of lipids by analysing the expression of chaperones

Grp78 (*Hspa5*), *Grp94* (*Hsp90b1*) and the apoptosis inducer *Chop* (*Ddit3*). All three

markers showed increased expression on a transcriptional level, indicating ongoing

UPR (Figure 2B, Table S1). Albeit not significant, *Creld2eGFP/eGFP* livers also presented

with higher Grp78 and Chop protein levels when compared to littermate controls

(Figure 2C, S1F). Thus, we analysed whether these changes led to activation of the

three UPR axes Atf6, Ire1 and Perk. Neither *Edem1* and *Derl3* as part of the ERAD

machinery and downstream targets of Atf6 [22], nor *Ire1* (*Ern1*) and *sXbp1* as part of the

Ire1 pathway showed significant differences in gene expression in male *Creld2eGFP/eGFP*

mice compared to controls (Figure 2B). Activation of the Perk pathway was determined

through the phosphorylation status of Perk and eIF2 as well as by protein expression

of Gadd34. We observed increased phosphorylation of PERK suggesting that

Creld2eGFP/eGFP livers experience ER stress, however, the signalling downstream of

PERK was not altered when compared to controls (Figure 2C). In line with the lack of

hepatosteatosis, livers of female *Creld2eGFP/eGFP* mice did not show major

transcriptional alterations in UPR or lipid metabolism pathways (Figure S2A-C).

Next, we addressed whether increasing levels of inflammation and tissue

damage, which are the basis for the progression of non-alcoholic fatty liver disease

(NAFLD) to non-alcoholic steatohepatitis (NASH), could be the leading cause of the

dysregulated metabolism. Intriguingly, qRT-PCR of pro-inflammatory cytokines (*Il1b,*

Il6, Tnfa) and acute phase response genes (*Apcs, Saa3*) revealed an overall

downregulation of these genes in *Creld2eGFP/eGFP* livers when compared to *Creld2WT/WT*

(Figure 2D, Table S1). Under steady state, tissue-resident macrophages, also called

Kupffer cells, are the main cytokine-producing cells in the liver. However, comparison

of their numbers revealed that Creld2$^{eGFP/eGFP}$ livers harbor rather more Kupffer cells

(Figure S2D), suggesting that the reduction of cytokine expression was not due to

reduced Kupffer cell numbers.

During inflammatory conditions such as hepatosteatosis, monocytes are

recruited to the liver where they differentiate into macrophages and become a source

of pro-inflammatory cytokines [23]. To test whether Creld2 deficiency affected the

production of cytokines by monocyte-derived macrophages, bone-marrow derived

macrophages (BMDMs) of 1-year-old male mice were treated with lipopolysaccharide

(LPS) and the expression of Tnfa, Il1b and Il6 was assessed after 4 h and 8 h of LPS

treatment (Figure S2E). Both Creld2$^{eGFP/eGFP}$ and Creld2$^{WT/WT}$ controls showed peaking

cytokine gene expression after 4 h, with decreasing expression levels at 8 h of LPS

stimulation, but no differences in transcript levels between both genotypes was

observed (Figure S2E). Taken together, Creld2-deficiency does not lead to severe

UPR or directly affects the immunological response. Instead, lack of Creld2 function

during steady state results in a subthreshold ER stress and decreased expression of

genes essential for lipid homeostasis, thereby evoking increased lipid storage in 1-

year-old Creld2$^{eGFP/eGFP}$ males.

Impaired cell survival in Creld2-deficient cells upon chronic ER stress

To better characterize a possible role of Creld2 in UPR we turned to an _in vitro_ system

and treated mouse embryonic fibroblasts (MEFs) from wildtype and Creld2$^{eGFP/eGFP}$

animals with increasing concentrations of the ER stress inducing agents tunicamycin

(Tm, 25–100 ng/ml) and thapsigargin (Tg, 2.5–10 nM) [24]. Untreated knockout cells

expanded similarly to wildtype MEFs, indicating that Creld2 is not required for cell

proliferation under steady state conditions (Figure 3A). Cell numbers of wildtype MEFs

increased at low concentrations or remained stable at higher concentrations of Tm and

Tg. However, *Creld2*-deficient MEFs were unable to cope with the induced stresses as

evidenced by reduced cell numbers after 3 days Tm treatment or 2 days Tg treatment,

independent of the dosage (Figure 3A). To test whether *Creld2*-deficient MEFs showed

a differential response to chronic ER stress we challenged the cells with the highest

concentrations of Tm (100 ng/ml) and Tg (10 nM) and analyzed UPR for up to 3 days

(Figure S3). Similar to wildtype controls, *Creld2*-deficient cells upregulated expression

of Grp78, Grp94 and Chop on transcriptional and protein levels (Figure S3A, B, I, Table

S2). Furthermore, responses in the Perk and Ire1a branches, as assessed by *Perk*

and *Gadd34* mRNA abundance, Gadd34 protein and P-eIF2a/eIF2a ratio as well as

expression of *Ire1a* and *sXbp1* transcripts, were comparable to controls (Figure S3C,

D, E, I).

Analysis of the Atf6 branch in *Creld2*$^{WT/WT}$ MEFs revealed that *Creld2* transcript

is highly upregulated after 24h of Tm and Tg (9 to 14-fold) and that protein levels

reached a 2-fold enrichment compared to steady state. However, *eGFP* expression in

Creld2$^{eGFP/eGFP}$ MEFs increased only ~2.5-fold on transcriptional level, and no change

in GFP protein levels could be detected (Figure S3F, G, I, Table S2), suggesting a

positive feedback loop for Creld2 expression during UPR in wildtype cells. Further, *Atf6*

expression was not altered in *Creld2*-deficient MEFs, however, the expression of Atf6

downstream targets *Edem1* and *Derl3* were downregulated throughout both the Tm

and Tg treatments in comparison to controls (Figure S3H, Table S2). Together, these

data suggested that Creld2 is indeed required for cell homeostasis and cell growth

under chronic ER stress conditions and that *Creld2*-deficiency may promote the

accumulation of misfolded glycoproteins, as the induction of ERAD-associated genes

Edem1 and *Derl3* was suppressed in *Creld2*-knockout MEFs.

Diminished UPR and cell survival in Creld2-deficient cells during ER-stress recovery

Complementary to the chronic ER-stress model, we set out to establish an ER-stress

recovery model where MEFs were treated for a short period of time (1-8 hours) with a

high concentration of Tg and then let recover for 5 days to mimic rather physiological

stress conditions. Successful induction of UPR within these 8 h was monitored by the

expression of _Grp78_, _Chop_, _Atf6a_, _Perk_, _Ire1a_ and downstream targets of the three

UPR axes (Figure S3J, Table S3). Already 2 h of Tg were sufficient to deteriorate the

survival of _Creld2_-knockout MEFs as evidenced by a significantly lower cell number

when compared to controls (Figure 3B). We therefore chose the 2 h time point to

investigate UPR during the 2-day recovery phase. To assess whether MEFs indeed

underwent UPR during the recovery phase, we first assessed the expression of

general ER-stress markers Grp78, Grp94 and Chop (Figure 3C, Table S4). _Grp78_ and

Chop expression peaked at 10 h, with significantly less production of _Grp78_ in

Creld2$^{eGFP/eGFP}$ MEFs at later time points (Figure 3C, Table S4). _Grp94_ expression

peaked at 30 h, however, _Creld2_-knockout MEFs showed a suppressed induction

throughout the recovery phase in comparison to controls (Figure 3C, Table S4). In

concordance with gene expression, Grp78 protein accumulated in both genotypes in

the beginning of the recovery phase (10 h), and increased even further at 30 h and 48

h albeit transcript levels declined (Figure 3C, D, S3K, Table S4). Similar to their gene

expression, Grp78 protein levels were lower in _Creld2$^{eGFP/eGFP}$_ MEFs compared to

wildtype controls during the recovery phase, while Chop was induced in a similar

manner in both genotypes (Figure 3D, Figure S3K). Together, these data hinted

towards an insufficient UPR in _Creld2$^{eGFP/eGFP}$_ MEFs, which prompted us to investigate

the activation of the three UPR axes.

Atf6a and _Edem1_ expression were induced similarly in knockout and wildtype

cells, but _Derl3_ expression was decreased in _Creld2$^{eGFP/eGFP}$_ MEFs (Figure 3E, Table

S4). In wildtype cells, *Creld2* mRNA expression was upregulated 6 h after Tg treatment

initiation and increased even further throughout the 2-day recovery phase with a peak

at 30 h (Figure 3E, Table S4). An accumulation of Creld2 protein was evident only after

30 h and increased even further after 48 h (Figure 3F, S3K). As a reporter for Creld2

expression we analyzed *eGFP* mRNA levels in *Creld2$^{eGFP/eGFP}$* MEFs. Although *eGFP*

increased in a similar temporal manner the expression reached a maximum of ~3.5-

fold in comparison to the starting point, while the endogenous *Creld2* expression was

increased to ~16-fold (Figure 3E, Table S4), which is similar to what we observed

under chronic stress conditions.

270   To investigate Perk axis activation, we measured transcript levels of *Perk* and

Gadd34 as well as phosphorylation of Perk and eIF2a proteins (Figure 3G, H, S3K,

Table S4). Although there was no difference on transcriptional level, with both *Perk*

and *Gadd34* being upregulated during the recovery phase (Figure 3G, Table S4),

Creld2-deficient MEFs displayed lower phosphorylation levels of Perk before and

during Tg treatment and the recovery phase (Figure 3H, S3K). Similarly, the P-

eIF2a/eIF2a ratio was diminished before ER-stress induction in *Creld2$^{eGFP/eGFP}$* MEFs

in comparison to *Creld2$^{WT/WT}$*. During the recovery phase, *Creld2$^{eGFP/eGFP}$* cells showed

a delayed phosphorylation of eIF2a with a peak after 30 h without reaching baseline

levels after 48 h, whereas *Creld2$^{WT/WT}$* MEFs exhibited increasing P-eIF2/eIF2 ratios

until 10 h followed by a decrease to baseline values after 30 h (Figure 3H, S3K).

281   In the Ire1a branch, *Creld2*-deficient and wildtype MEFs showed a similar

behavior after the ER-stress challenge: both, *Ire1a* gene expression and splicing of

Xbp1 (*sXbp1*) during the recovery phase was increased, and remained at high levels

after 48 h (Figure 3I, Table S4). In summary, our data indicate that UPR within the Atf6

and Perk axes is partially deteriorated or delayed in *Creld2*-deficient cells leading to

their diminished cell growth and increased apoptosis.

Accumulation of lipids does not lead to UPR

Given that Creld2 is required for a proper mounting of UPR and that aged

Creld2$^{eGFP/eGFP}$ mice develop hepatosteatosis and show elevated Grp78, Chop and P-

Perk protein levels, we next asked whether the prolonged accumulation of lipids

causes unresolved ER stress in these animals or vice versa. To induce the

development of fatty liver, we placed 8-week-old *Creld2$^{eGFP/eGFP}$* males and wildtype

littermates on control diet (CD) or high-fat diet (HFD). To test whether animals could

recover from hepatosteatosis, we split the HFD group after 8 weeks with one group

remaining on HFD for 4 more weeks and one group that was switched to CD (HFD>CD,

Figure 4A). Supporting our findings in aged mice (Figure 1B), we found that

Creld2$^{eGFP/eGFP}$ animals on CD gained less weight over time (Figure 4B). Similarly, after

8-12 weeks on HFD *Creld2$^{eGFP/eGFP}$* showed reduced bodyweights when compared to

littermate controls (Figure 4B), but still developed insulin resistance as measured by

the homeostatic model assessment indices of insulin resistance (HOMA-IR) (Figure

4C). Moreover, both genotypes increased the total tissue weight of livers and

epididymal white adipose tissue (eWAT) (Figure 4D) indicating that *Creld2$^{eGFP/eGFP}$*

animals were not protected from diet-induced obesity.

Histological assessment of the liver showed an increased ORO staining in HFD-

fed mice (Figure S4A, B), which was accompanied by a small decrease in PAS signal

(Figure S4C, D) confirming diet-induced hepatosteatosis in both genotypes.

Accumulation of lipids in general, which resulted mainly from TAG and DAG

accumulation, was confirmed by shotgun lipidomics (Figure 4E). *Creld2$^{eGFP/eGFP}$* livers

contained generally less lipids (Figure 4E), which could account for the on average

lower liver weight (Figure 4B). HFD did not induce a fibrotic phenotype, nor did it affect

liver function as assessed by MGT staining (Figure S4E, F) and alanine

aminotransferase (ALT) concentrations in the serum (Figure S4G), respectively. When

the HFD groups where switched to CD, their body, liver and eWAT weight returned to

the level of animals that were kept on CD (Figure 4B, D). Further, ORO and PAS

signals as well as the amount of lipids normalized in both genotypes (Figure 4D, E,

S4A-D). Together, our data indicate that on organismal and tissue level *Creld2*-

deficient mice responded similarly to wildtype mice upon diet-induced obesity and lipid

uptake as well as mobilization of lipids after a diet switch from HFD to CD.

To test whether lipid accumulation or subsequent lipid mobilization triggered

differential cellular stress responses in *Creld2$^{eGFP/eGFP}$* and littermate control livers, we

performed RNA-sequencing (RNA-seq) after 12 weeks on diet (Figure S4H). We made

use of Construction of Co-expression network analysis (CoCena) that clusters genes

into distinct modules based on the expression patterns across the two genotypes and

three conditions. CoCena identified a module (purple), which contains genes being

highly expressed after HFD>CD recovery, but which are also globally upregulated in

Creld2$^{eGFP/eGFP}$ livers when comparing them to *Creld2$^{WT/WT}$* in each condition (Figure

4F, Table S5). Gene Ontology (GO) and Hallmark terms indicated that many of the

833 genes were involved in the regulation of fatty acid metabolic processes as well as

in the ERK signaling cascade. Among these genes were *Plin2*, which belongs to the

perilipin family and serves as a marker for lipid accumulation, as well as genes coding

for enzymes catalyzing the formation of distinct lipid species (*Acot2*, *Eci2*, *Chka*,

Mogat1, *Pnpla2*, *Elovl5*, *Pck1, Gpat3, Crot)*, lipid transfer and lipid uptake proteins

(*Tnfaip8l3*, *Scarb1*, *Sorl1*, *Lrp10*), and proteins regulating insulin signaling (*Irs1, Insig2,*

Angptl4, Igfbp3, Cltrn, Slc16a1) (Figure 4G). Many of these genes are correlated to

fatty acid oxidation and hepatic lipid mobilization, which may explain why

Creld2$^{eGFP/eGFP}$ livers show reduced lipid amounts as they upregulate these genes

even more than *Creld2$^{WT/WT}$* after HFD>CD recovery. This is in contrast to what we

observed in aged mice, where enzymes such as *Acox1* and *Acot2* are downregulated

(Figure 2A), suggesting that Creld2 is not directly regulating metabolic gene

expression, similarly to what has been reported for *Atf6*-knockout mice [15].

Further, CoCena identified the royalblue module (63 genes) with globally

upregulated genes in *Creld2^eGFP/eGFP* livers showing highest differences after CD and

HFD (Figure 4F). GO and Hallmark enrichment analyses indicated an enrichment for

mRNA processing and apoptosis. Additionally, the black module that showed an

induction of 126 genes in *Creld2^eGFP/eGFP* livers after HFD also returned 'apoptosis' as

GO term suggesting that knockout livers may have increased mRNA levels and

undergo apoptosis due to unresolved ER stress. This notion was supported by an

increase of ceramides in *Creld2^eGFP/eGFP* livers after HFD (Figure 4H), as their

accumulation has been associated to apoptosis in hepatosteatosis [25]. Indeed,

immunoblotting against cleaved Caspase3 confirmed that *Creld2^eGFP/eGFP* livers after

HFD underwent increased apoptosis when compared to *Creld2^WT/WT* (Figure 4I, S4H).

The module midnightblue identified 703 genes that were generally

downregulated in *Creld2^eGFP/eGFP* livers when compared to controls, particularly after

the diet switch from HFD to CD, and that were involved in protein folding and long-

chain fatty acid metabolism based on GO enrichment analysis. Among these genes

were cytochrome p450 genes that oxidize polyunsaturated fatty acids (PUFA), which

may lead to an increase of lipotoxic ω-6 PUFA [26] in *Creld2*-deficient livers. Moreover,

chaperones and co-chaperones (*Hspa4l, Hsp90aa1, Fkbp4, Dnaja4, Unc45b, Hspa13,*

Calr) including *Hspa5* (*Grp78*) were downregulated (Figure 4G). We therefore

investigated whether Grp78 expression and UPR activation were affected on the

protein level. Yet, neither Grp78 nor phosphorylation levels of Perk and eIF2a were

significantly changed in *Creld2^eGFP/eGFP* livers when compared to littermate controls,

(Figure 4J, S43H). Further, the comparison of CD versus HFD groups per genotype

did not reveal any sign of induced ER stress on transcript or protein level (Figure 4G,

J), with Grp78 and Chop expression being even downregulated after HFD when

compared to CD (Figure 4J). To test for other targets of the UPR that might be affected

by the dietary change and that may have not been included in the CoCena analysis,

we additionally performed a direct pairwise comparison of differentially expressed

genes between CD or HFD *Creld2^{WT/WT}* or *Creld2^{eGFP/eGFP}* animals. None of these

analyses returned genes involved in UPR (Table S6) indicating that 12 weeks of HFD

do not induce acute ER stress in the liver. Taken together, our data suggest that

Creld2^{eGFP/eGFP} animals can generally cope with an excess of lipid uptake for a short

time period of 12 weeks, despite transcriptional changes that hint towards altered lipid

metabolic processes. Furthermore, neither transcriptome nor protein expression

analysis revealed a lipid-driven ER stress response in the liver, despite an enhanced

lipotoxicity phenotype in *Creld2^{eGFP/eGFP}* mice.

Unresolved ER stress perturbs hepatic lipid homeostasis in livers of Creld2-deficient

mice

Next, we turned to the question whether unresolved ER stress induces the observed

hepatosteatosis phenotype in *Creld2^{eGFP/eGFP}* mice. To this end *Creld2^{eGFP/eGFP}*

animals and littermate controls received a single intraperitoneal injection of the ER

stressor Tm (1mg/kg), Tg (0.5 mg/kg) or sucrose as control and mice were analyzed

after two days (Figure 5A). Histological analyses as well as shotgun lipidomics

indicated that *Creld2^{WT/WT}* livers did not accumulate lipids or glycogen after Tg

injection, while an increase of lipids and glycogen after Tm injection could be observed

(Figure 5B, C, S5A-C). The moderate lipid storage in *Creld2^{WT/WT}* animals largely

resulted from accumulation of cholesterol and cholesterol esters (Figure 5C). Also

Creld2^{eGFP/eGFP} animals did not present with increased lipid levels after Tg treatment

(Figure 5B, C, S5A-C). However, *Creld2^{eGFP/eGFP}* livers stored more lipids than

Creld2[WT/WT] controls after Tm treatment, which could be mainly attributed to

augmented TAG, DAG and cholesterol ester abundance (Figure 5B, C). This fatty liver

phenotype was accompanied by a decreased PAS signal when compared to controls

(Figure 5B, S5C), similarly to the phenotype observed upon HFD-induced

hepatosteatosis. Further, MGT revealed an increased collagen storage after Tm

treatment in both genotypes (Figure S5D-E).

To identify the molecular mechanisms that lead to augmented lipid

accumulation in *Creld2*[eGFP/eGFP] mice after ER-stress induction with Tm and to

characterize the distinct tissue response after treatment with Tg, we performed RNA-

seq on livers and analyzed the gene expression using principle component analysis

(PCA, Figure S5F) and CoCena (Figure 5D, Table S7). The darkorange module (1257

genes) contains genes that were upregulated after Tm treatment in both genotypes

when compared to untreated mice, however, with even a higher expression in

Creld2[eGFP/eGFP] livers. KEGG pathway and GO enrichment returned terms such as

'NAFLD', 'glycoprotein metabolic process' and 'response to ER stress' (Figure 5D),

which comprised UPR- (*Atf6, Hspa5, Hsp90b1, Ern1*) and ERAD-related genes (*Derl1,*

Derl3, Edem1, Pdia3, Pdia4, Sel1, Erlec1) (Figure 5E). Tm treatment prevents protein

glycosylation, which in turn induces ER stress and lipid accumulation [15] (Figure 5B, C).

Wildtype livers largely recover from Tm-induced lipid perturbations after 2-3 days while

keeping part of the UPR active, e.g. expression of chaperones Grp78 and Grp94 [15,24].

Our data validate these observations showing that UPR is active after 2 days of Tm

treatment and further suggest that *Creld2*[eGFP/eGFP] livers undergo elevated ER stress

when compared to *Creld2*[WT/WT] controls. Yet, despite the increased UPR and ERAD

response on transcriptional level, *Creld2*[eGFP/eGFP] mice are unable to resolve ongoing

ER stress and thus present with increased hepatic lipid storage, supporting the active

role of Creld2 during UPR and subsequent ER protein processing capacity. In line with

this hypothesis, the module skyblue (273 genes) classified genes that are specifically

upregulated in *Creld2^eGFP/eGFP* livers after Tm treatment (Figure 5D). GO enrichment

analysis of genes in the skyblue module included mainly terms related to 'mRNA

processing' as well as 'regulation of translational initiation', suggesting that *Creld2*-

deficient livers do not attenuate translation upon ER stress.

The module mediumorchide identified 298 genes that were globally

downregulated in *Creld2^eGFP/eGFP* livers, with highest differences after Tm treatment

(Figure 5D). These genes enriched largely for 'lipid homeostasis' and 'glucose

metabolic process' as determined by GO enrichment analysis. Among enzymes

regulating metabolism homeostasis were *Dgat1*, *Dgat2*, *Abcd1*, *Acsm5*, *Cry2*, *Mup1*,

Ormdl3, and *Nr1h2* (lipid synthesis and storage) as well as *Adipor1* (glucose uptake)*,*

Pklr, Shc1, Ppp1r3b, and *Serpina12* (insulin response). The downregulation of hepatic

metabolism genes is in concordance with the phenotype observed in aged

Creld2^eGFP/eGFP animals, arguing that accumulating ER stress in old Creld2-deficient

livers is responsible for these transcriptomic changes. Further, *Creld2^eGFP/eGFP* livers

presented with a set of downregulated genes involved in biological processes of

protein catabolic processes (*Ppp1r15a*, *Grina, Creb3, Pdia2, Tmem259, Atg4b)*,

proteasome degradation (*Sqstm1, Rnf185, Rnf187, Fbxw5, Hectd3, Lrrc41, Ube3b,*

Psmb5) as well as (co)-chaperones (*Sgta, Hspbp1, Cdc37, Hspb6*), indicating that

catabolic processes induced upon ER stress to lower the protein load are attenuated

in a Creld2-dependent manner (Figure 5E).

Of note, the brown module contained 713 genes that were specifically

upregulated after Tg treatment in both genotypes and GO and Hallmark enrichment

analyses returned terms such as 'humoral immune response' and 'complement and

coagulation cascade', indicating that liver metabolism or the UPR is not affected by Tg

treatment. Taken together, our transcriptomic data show that *Creld2^eGFP/eGFP* livers

efficiently induce the Atf6-dependent arm of the UPR and activate major components

of the ERAD machinery. Yet, the downregulation of genes within the E3-ubiquitin-

protein ligase complex and autophagosome suggests a dysfunctional UPR, which may

eventually result in increased protein accumulation due to inefficient protein

degradation.

To test this hypothesis, we first analyzed Grp78 protein abundance after Tg and

Tm treatment as an indicator for protein accumulation in the ER lumen. Similar to RNA-

seq results, Grp78 was upregulated in wildtype animals after Tm when compared to

control treatment, but was even more abundant in *Creld2eGFP/eGFP* livers (Figure 5F,

S5G). Of note, both GFP expression in *Creld2eGFP/eGFP* and Creld2 expression in

Creld2WT/WT littermate controls was increased upon both treatment conditions (Figure

5F, S5G), rendering Creld2 expression and the *Creld2WT/eGFP* mouse as an efficient

tool to monitor cellular stress. We next tested the activation of the Perk-axis via

analysis of Perk and eIF2a phosphorylation and Gadd34 protein abundance. Despite

the increased levels of Gpr78, we did not detect enhanced activation of the Perk-axis

in *Creld2eGFP/eGFP* livers (Figure 5F, S5G). In summary, induction of ER stress via Tm

partially recapitulates the phenotype observed in aged *Creld2eGFP/eGFP* animals

including increased Grp78 expression and hepatic lipid storage, supporting the notion

that Creld2 is required to maintain tissue homeostasis in order to prevent lipid

accumulation due to long-lasting and unresolved ER stress.

Creld2 interaction partners

To investigate the molecular function of Creld2 in UPR and metabolic homeostasis we

performed co-immunoprecipitation experiments by tandem affinity purification [27] and

subsequent mass spectrometry. We used mouse Creld2 tagged either on the N- or C-

terminus to exclude inhibition of protein binding due to the fused Strep-Flag tag.

Moreover, Creld2 constructs were either transiently expressed (72 h) or stably

integrated into the genome of HEK239 cells (Figure 6A) to *i)* enable the

characterization of specific interactions with chaperones since a strong transient

overexpression increases the unspecific co-purification of heat shock proteins [27] and

ii) select for highly conserved interactions, which would also occur in this inter-species

(mouse-human) setup. Using a stringed filtering pipeline and imputation (Figure 6B,

see also methods), we found 31 putative interaction partners (Figure 6C, Table S8).

Analysis for GO enrichment returned terms such as 'response to ER stress', 'protein

folding', and 'cell redox homeostasis' (Figure 6D). Many chaperones and protein

disulphide-isomerases (PDI) were present in the transient condition (C2-SF trans),

some of which (HSPA8, HSP90B, HYOU1) have been previously proposed to interact

with Creld2 [28]. However, since these proteins were not enriched in the stably

transfected cells (FS-C2 stab and C2-SF stab) we propose that these represent

unspecific co-purification products [27] underlining the constraints of co-

immunoprecipitation assays in transiently transfected cell lines.

We thus focused our analysis on candidates present in at least 2 conditions,

which contained CRELD2 itself, as expected, as well as HSPA5 (GRP78), thioredoxin

domain-containing 5 (TXNDC5) and glutathione S-transferase Mu3 (GSTM3) (Figure

6C). Interaction with GRP78 [28] confirms the active role of Creld2 in regulating UPR, as

it may sequester the chaperone away from Perk/Atf6/Ire1, thereby, promoting the

activation of the three UPR axes. TXNDC5, also known as endo PDI, is a thioredoxin

peroxidase whose expression is regulated by ATF6 and sXBP1. Functionally it is

proposed to reduce misfolded protein load [29]. Intriguingly, also Creld2 has been

proposed to have PDI-like functions [28], hinting towards a synergistic mechanism

between these proteins to resolve ER stress. GSTM3 is a member of the glutathione

S-transferases superfamily that promotes detoxification of reactive oxygen species

(ROS) [30]. Oxidative stress and UPR are tightly interlinked, exemplified by PERK being

upstream of the transcription factor NRF2 that counteracts the toxic effects of ROS

produced upon ER stress during protein folding, e.g. via PDI activity [31]. Thus, the

interaction of Creld2 with GSTM3 may represent an additional point of crosstalk

between these cellular stresses. In summary, our data strengthen the hypothesis of an

active involvement of Creld2 in UPR via interaction with chaperones and enzymes,

whose activity is required to overcome cellular stress.

<u>CRELD2 expression in human liver disease</u>

Overall, our data suggested that Creld2 function is required to maintain hepatic

homeostasis under physiological conditions during aging as well as during ER stress

responses in mice. Therefore, we next asked whether human CRELD2 would play a

role under pathophysiological conditions in the liver and analysed a cohort of 57 obese

patients with varying severity of non-alcoholic fatty liver disease (NAFLD) and 4

controls for CRELD2 expression. We first divided patients into two groups - with or

without NASH as diagnosed using the SAF (Steatosis, Activity and Fibrosis) score [32].

Intriguingly, both CRELD2 transcript and protein levels in the liver were significantly

upregulated in male patients with NASH, while expression in female patients remained

unaffected (Figure 7A). Control patients showed similar expression to NAFL patients.

To test whether secreted CRELD2 could be used as a diagnostic marker for NAFLD

severity we plotted the serum concentration of CRELD2 against the SAF score (Figure

7B). While no correlation was observed in female patients, males had an inverse

correlation with low levels of CRELD2 at higher SAF scores, which may hint towards

a retention mechanism for CRELD2 in the tissue during hepatic pathophysiology. In

summary, CRELD2 shows a sex-specific function during NAFLD in humans with an

intra-hepatic upregulation of CRELD2 expression, which seems to be associated with

progression to NASH in male patients.

Discussion

Our study shows that Creld2 plays an active role during UPR *in vitro* and *in vivo* and

contributes to the overall maintenance of cell homeostasis and resolution of ER stress

conditions. Using the newly generated *Creld2$^{eGFP/eGFP}$* transgenic mouse model, we

characterized the stress response of *Creld2*-deficient cells. After challenge with Tm

and Tg, *Creld2*-deficient MEFs show perturbated induction of UPR, which ultimately

leads to their decreased survival. Dysregulation of UPR in *Creld2*-deficient MEFs is

evidenced by decreased or delayed induction of target genes and activation of proteins

within the Atf6 and Perk axes, including chaperones and ERAD machinery

components. Our *in vitro* data thus support the hypothesis that Creld2 is required to

protect cells against ongoing stress, although the cells retain the ability to partially

compensate through other signalling pathways.

Analysis of Creld2 interaction partners further strengthen its protective role

during the late phase of UPR: Creld2 protein accumulates 24-48h after induced ER

stress and has the capacity to bind to Grp78, which would in turn prohibit Grp78 from

binding to and inactivating Perk/Ire1/Atf6. Through this interaction, Creld2 may serve

as a positive feedback loop for UPR, thereby promoting continuous activity of the UPR

axes during long-lasting stress conditions. Further, Creld2 binds to the endo PDI

Txndc5 and glutathione S-transferase Gstm3, two proteins important for protein load

reduction and ROS detoxification, respectively. How binding to Creld2 influences the

function of these proteins remains to be investigated. Nevertheless, we propose that

Creld2 has a dual role during cellular stress: it keeps UPR elevated, most likely by

modulating the Perk- and Atf6-dependent axes through binding to Grp78, and at the

same time it contributes to the reduction of misfolded proteins either through its own

PDI activity or by promoting the PDI activity of Txndc5 and detoxification function of

Gstm3.

In line with our *in vitro* results, Creld2 function is a prerequisite *in vivo* particularly

in hepatocytes, a cell type that constantly undergoes increased levels of stress due to

its homeostatic function in the liver [33]. Albeit young animals can compensate for *Creld2*

deficiency, aged *Creld2eGFP/eGFP* animals present with a heightened UPR in the liver,

increased   lipid   accumulation,   and   disrupted   glucose   homeostasis.   Since

Creld2eGFP/eGFP animals are generally not obese and show intact hepatic insulin

sensitivity, the long-lasting subthreshold UPR during ageing may indirectly contribute

to the observed systemic insulin resistance and glucose intolerance by promoting fat

accumulation in hepatocytes through the downregulation of lipid homeostasis

enzymes.

To test this hypothesis, we examined the line of causality between

hepatosteatosis and UPR by challenging young mice with Tm or Tg for 2 days or by

diet-induced obesity. We found no evidence that lipid accumulation through HFD *per*

se induces UPR in wildtype or *Creld2eGFP/eGFP* livers. Yet, livers from *Creld2eGFP/eGFP*

animals show first signs of cellular stress and apoptosis when compared to controls,

which underlines the UPR-independent protective function of Creld2 upon oxidative

stress and ceramide-mediated hepatotoxicity caused by HFD [34,35]. Further, the diet

switch from HFD to CD did not promote ER-stress induction in both genotypes, but

rather reduced the expression of chaperones and induced genes important for lipid

homeostasis in *Creld2eGFP/eGFP* livers. Thus, we conclude that UPR does not play a

major role during diet-induced hepatic steatosis as long as this pathophysiology is

reversible and did not progress to NASH.

Despite a clear UPR induction in MEFs, our transcriptomic analysis in mice

confirmed that – in contrast to *in vitro* studies - *in vivo* treatment with Tg induced rather

hepatic inflammation and not ER stress [36]. Conversely, treatment with Tm led to

hepatic steatosis in *Creld2^eGFP/eGFP* males mimicking the phenotype observed in aged

knockout animals. The increased hepatic lipid storage was accompanied by a

disrupted regulation of metabolic genes as well as a heightened ER stress and ERAD

response. However, despite enhanced UPR the tissue failed to induce proteasomal

catabolic processes indicating that *Creld2^eGFP/eGFP* hepatocytes are unable to return to

homeostatic conditions. Thus, we conclude that *in vivo* Creld2 deletion sensitizes cells

to ER stress particularly in the liver, thereby, leading to long-lasting stress due to failure

of the protein folding and degradation machinery, which results in the observed tissue-

specific phenotype. The elevated stress response to Tm in the liver is in contrast to

what we observed *in vitro* where *Creld2^eGFP/eGFP* MEFs failed to upregulate some

components of UPR signalling pathways upon Tg treatment. This could be due to the

time frame that cells experience Tg/Tm, to the distinct ER stressor, or may be

dependent on the cell type, underlined by the fact that Tg failed to induce hepatic ER

stress.

Similar to *Creld2*-deficient cells and mice, *Atf6*-knockout MEFs and animals

challenged with the ER stress-inducing agent Tm undergo persistent cell stress as they

are unable to upregulate ER chaperones and genes involved in ERAD. As a direct

consequence of this ongoing ER stress, metabolic genes are downregulated in the

liver [15]. Since Creld2 expression is regulated by Atf6 and *Creld2^eGFP/eGFP* animals

suppress expression of genes maintaining lipid homeostasis even under unchallenged

conditions, we hypothesize that Atf6 restores overall cell homeostasis in a Creld2-

dependent manner. In this scenario Creld2 may be a candidate for a cross-talk

between the Atf6 and Perk pathway or between the UPR and protein folding machinery

(Figure 7C).

Intriguingly, we observed a sex dimorphism in aged mice, with only

Creld2$^{eGFP/eGFP}$ males presenting with steatosis while females were protected,

indicating that long-lasting unresolved ER stress induces hepatic pathophysiology

primarily in males. Sex differences in fatty liver diseases have been demonstrated both

in rodent models and in human disease [37]. NAFLD is more prevalent in men and

postmenopausal women compared to premenopausal women, which is mostly

attributed to hormone homeostasis and visceral fat accumulation [37,38]. However, we

did not observe general obesity or increased fat accumulation outside the liver in male

Creld2$^{eGFP/eGFP}$ mice. We therefore favor the hypothesis that the hepatic ER stress

response is sex dependent and thus a risk factor for the development of NAFLD and

progression to NASH or hepatocellular carcinoma (HCC) particularly in males. This is

in line with our results showing that CRELD2 accumulates only in livers of male NASH

patients, as well as a previous study demonstrating that kidneys of male mice are more

susceptible to ER stress-induced acute kidney injury than those of females due to a

testosterone-dependent mechanism [39]. Further, CRELD2 - among six other proteins

that maintain ER homeostasis - was identified as an adverse prognostic biomarker for

overall survival in HCC patients [40] underlining that elevated and unresolved ER stress

can promote liver pathophysiology. Therefore, it will be essential to take the sexual

dimorphism into account in the future when studying the contribution of ER stress to

hepatic steatosis as well as in the course of NAFLD treatment with UPR inhibitors.

Materials and methods

Mouse work

For the generation of a conventional *Creld2*$^{eGFP/eGFP}$ mouse the open reading frame (ORF) of the *Creld2* gene was replaced by an enhanced green fluorescent protein (eGFP) and a neomycin resistance cassette (neoR) flanked by two FRT sites via homologous recombination. False positive ES cell clones were excluded by a diphtheria toxin A (DTA) cassette, which was introduced after the 3' homologous region of the targeting vector. Positive ES cell clones were selected by PCR against the neoR cassette and confirmed by southern blot via an internal and 5' external probe. Heterozygous Creld2$^{WT/eGFP/neo}$ offspring from blastocyst injections of positive ES cell clones were crossed with mice ubiquitously expressing FLP recombinase for excision of the neoR cassette. neoR deletion was confirmed by PCR. Mice were provided with standard chow and autoclaved water ad libitum. Genotyping primers: Creld2 wt genotype fw 5'-CCTGAGCTGTCCTTAGAAAGTTGCTAG-3', Creld2 ko genotype fw 5'-GCCCGACAACCACTACCTGAGC-3', Creld2 genotype rev 5'-GGGGTTCATGTCCATGGGCCAC-3'.

For glucose tolerance test (GTT), mice were fasted for 6 h with supply of drinking water ad libitum. Fasting blood glucose (0 min) was measured and mice were injected with 2 g/kg glucose solution intraperitoneally (i.p.) and blood glucose was measured after 15, 30, 60, 90, and 120 min. Blood samples were drawn from the tail tip of the mice. Mice subjected to insulin tolerance test (ITT) had access to chow and drinking water ad libitum before and throughout the experiment. Initial blood glucose (0 min) was measured and mice were administered 0.75 U/kg insulin by i.p. injection and blood glucose was measured as described for GTT.

To test hepatic insulin resistance, mice were fasted for 6 h with supply of

drinking water ad libitum prior to i.p. injection of glucose (2 g/kg). Mice were sacrificed

15 min after glucose administration and livers were harvested for further analysis.

To induce hepatic UPR, 8-9 weeks-old male mice were administered with Tg

(0.5 mg/kg), Tm (1 mg/kg) or a vehicle control sucrose solution (150 mM) via i.p.

injection and sacrificed after 48 h.

For HFD experiments, male mice received standard chow until 6 weeks of age.

Afterwards, standard chow was replaced by a control diet (CD; metabolizable energy:

62 % from carbohydrates, 11 % from fat, 27 % from protein; ssniff EF D12450B* mod.

LS) for 2 weeks prior to the beginning of the experiment. Subsequently, 8-week-old

mice were either fed with CD or HFD (metabolizable energy: 22 % from carbohydrates,

54 % from fat, 24 % from protein; ssniff EF acc. D12492 (I) mod.) for 12 weeks or mice

were kept on HFD for 8 weeks and CD for 4 weeks (HFD>CD). Mice were weighed

once a week. For the determination of the Homeostatic model assessment of insulin

resistance (HOMA-IR) [41], mice were fasted for 6 hours and blood was drawn from 8-

week-old mice at the beginning of the feeding period and from mice being fed CD or

HFD for 8 weeks. Blood samples were analyzed for blood glucose using a glucose

meter (Accu-Chek, Aviva) and blood serum insulin levels (Mouse Insulin Elisa kit,

Thermo Scientific) according to the manufacturers' instructions. HOMA-IR indices

were calculated using the formula: (Glucose (mg/ml) x Insulin(µU/ml))/405.

$\dfrac{Glucose\ (mg^{ml-1}) \times Insulin\ (\mu U^{ml-1})}{405}$

All mice were kept under standard SPF housing conditions according to the

approved animal license 84-02.04.2014.A335 with a 12 h dark/light cycle.

Histological stainings

For paraffin stains, tissues were fixed in 4% PFA (Thermo Scientific). After fixation, tissues were dehydrated, paraffin embedded and cut at a thickness of 5 µm. Subsequently, sections were deparaffinized, rehydrated and stained with Hematoxylin followed by Eosin (VWR), PAS (Roth) or MGT (Merck) according to the manufacturer's protocol. After dehydration, tissues were mounted in Entellan. For Cryo-embedded (Tissue-Tek, Sakura) tissue stains, sections were fixed in 4% PFA and stained with freshly prepared Oil-red-O (Sigma-Aldrich) working solution according to the manufacturer's instructions followed by mounting in Kaiser's glycerol gelatine (Merck). Quantitative analyses of PAS, MGT and ORO stainings were done using ImageJ2 software. Scripts for quantifications are provided at: https://github.com/maccabaeus/histological-evaluation.git

qPCR

RNA was isolated using the Nucleospin RNA II kit (Macherey & Nagel) according to the manufacturer's instructions and reverse transcribed into cDNA by using the QantiTect reverse transcription kit (Qiagen) according to the manufacturer's instructions. For qRT-PCR reactions, primer pairs (see Table S9 were mixed with cDNA and iQ SYBR´Green Supermix (Bio-Rad), and qRT-PCR was run on an iQs Real-Time PCR Detection System (Bio-Rad). Genes of interest were normalized to the reference genes *Ppia* (peptidylprolyl isomerase A) and *Hprt* (hypoxanthine-guanine phosphoribosyltransferase) for calculation of the Delta-Delta Cq value by the inherent qRT-PCR evaluation software CFX manager (Bio-Rad). For human *CRELD2* gene expression levels analysis *HPRT* was used as reference gene. Relative gene expression was calculated from the threshold cycles in relation to the reference gene and controls without NAFLD. Reactions were performed on a CFX96 Touch qPCR

System (Bio-Rad). To represent qRT-PCR as heatmaps, gene expression data

(housekeeper normalized delta delta Cq values) were scaled to individual genes

separately for each gender prior to averaging and plotting of heatmaps using the

pheatmap R-package.

Bone marrow-derived macrophage (BMDM) isolation and LSP treatment

Femur and tibia of sacrificed mice were dissected and flushed with PBS using a 26G

needle and cultured in DMEM (Invitrogen) medium supplied with 10% FCS (Pan

Biotech), 1% Pen-Strep (10000 U/mL; Thermo Scientific), 20% L929 cell medium

supernatant for 6 days. Subsequently, differentiated BMDMs were stimulated with LPS

(200 ng/ml; from *Escherichia coli* O111:B4; Sigma-Aldrich) for 4-8 h.

Kupffer cells flow cytometry

Livers were harvested and incubated in digestion buffer (PBS, 1 mg/ml collagenase D

(Roche), 100 U /ml DNase I (Sigma-Aldrich), 2.4 mg/ml dispase (Invitrogen), 3% FCS

(Invitrogen)) at 37°C for 30 min prior to mechanical disruption by straining through a

100 μm cell filter. Cell suspensions were centrifuged at 50 g for 3 min to sediment

hepatocytes, supernatants were recovered, centrifuged at 320 g for 7 min and

incubated in FACS buffer (PBS, 0.5% BSA, 2 mm EDTA) containing anti-CD16/32

(1:100 dilution), 5% normal mouse, 5% normal rabbit and 5% normal rat serum for 15

min at 4°C. After the incubation, cells were immunostained with antibody mixtures

(CD45-APC/Cy7 (30-F100), CD11b-PECy7 (M1/70), F4/80-BV421 (BM8), Tim4-

AF647 (RMT4-54) (all from Biolegend)) for 30 min at 4°C. Single live cells were

selected by excluding dead cells (Hoechst 33258, 1:10.000), gating on side (SSC-A)

and forward scatter (FSC-A) and excluding doublets using forward scatter width (FSC-

W) against FSC-A. Kupffer cells were identified by gating on CD45$^+$, CD11b^{low},

F4/80$^+$Tim4$^+$ cells.

Cell culture

Pregnant mice were sacrificed and embryos (E12.5) were obtained. Heart and liver of

embryos were removed and embryo bodies were incubated in trypsin-EDTA (Thermo

Scientific) for 30 min at 37°C with shaking at 900 rpm. After digestion, cells were

centrifuged at 100 g for 5 min, washed once with DMEM and cultured in DMEM at

37°C. Experiments were conducted on cells at passage 4. For acute ER stress

induction 0.5x10^6 MEF cells were treated with 1 µM Tg for 1-8 h and either harvested

for further analysis, or split and 1x10^4 cells were seeded out in a 24-well plate and

cultured for another 5 days in DMEM without Tg for cell viability analysis. For recovery

experiments, MEFs were treated with 1 µM Tg for 2 h and further cultured without ER

stressor for up to 46 h. For induction of chronic ER stress, cells were treated with Tg

(2.5, 5, 10 nM, Sigma-Aldrich) for up to 48 h or Tm (25, 50,100 ng/ml, Sigma-Aldrich)

for up to 72 h. Control cells (0 h) were cultured in DMEM supplied with DMSO mock.

For crystal violet survival assays, MEFs were fixed with Histofix 4% (Roth) for 5 min,

stained with Crystal violet (0.05% in ddH$_2$O; Roth) for 30 min followed by washing twice

with tap water and subsequent air-drying. After drying, dye was solubilized by addition

of MeOH and staining intensity was measured photometrically at 590 nm (Fluostar

Omega; BMG Labtech).

Library preparation for RNA sequencing

mRNA was converted into libraries of double stranded cDNA molecules as a template

for high throughput sequencing following the SMART-Seq2 protocol [42]. Shortly, mRNA

was primed for SMART reverse transcription from 5 ng of total RNA using poly-T oligos.

cDNA was pre-amplified by SMART ISPCR. Fragmentation was performed using the

Illumina Nextera XT kit, followed by PCR amplification and indexing. Size-selection

and purification of library fragments with preferentially 300-400 bp in length was

performed using SPRIBeads (Beckman-Coulter). The size-distribution of cDNA

libraries was measured using the Agilent high sensitivity D5000 assay on a Tapestation

4200 system (Agilent). cDNA libraries were quantified using a Qubit high sensitivity

dsDNA assay. 75 bp single-end sequencing was performed on a NextSeq500 system

using High Output v2.5 chemistry. Base calling from base call files, alignment to the

Mus musculus reference genome mm10 from UCSC and file conversion to fastq files

were achieved by Illumina standard pipeline scripts (STAR version, bcl2fastq2 v.2.20).

RNA sequencing analysis

Kallisto [43] was used to quantify abundances of transcripts - read counts - from the bulk

RNA-seq data. The kallisto read counts were used as input to DESeq2 [44] for calculation

of normalized signal signal and differentially gene expression analysis. Genes are

excluded from the analysis where the total read count of all samples is less than 10.

This pre-filtering step removes genes in which there are very few reads, in order to

reduce the memory size, and to increase the speed of the calculation. The diet and

drug induced ER-stress dataset then comprised 17340 and 17280 genes respectively.

DESeq Dataset (dds) was created to store the read counts and the intermediate

estimated quantities with a merged design formula consist of genotype ($Creld2^{WT/WT}$ or

$Creld2^{eGFP/eGFP}$) and condition (dietary or pharmacological). The quality control of the

samples shows the variance of the read counts between the samples, where dds was

used as an input file. Variance stabilizing transformations (VST) were used for the

downstream analysis (clustering). VST produces transformed data on the log2 scale

which has been normalized with respect to library size. Date of experiment was

modelled as a known batch factor using the "Linear Models for Microarray and RNA-

Seq Data" (Limma) package [45]. Unwanted surrogate variables were estimated and

modelled via Surrogate Variable Analysis (SVA) [46] using the method called leek. In the

diet related experiment 22 surrogate variables (SV) were identified and 3 of them

modelled. The top 5000 variable genes were selected and used as an input for co-

expressional   network   analysis   using   CoCena2

(https://github.com/UlasThomas/CoCena2). Person correlation analysis was performed

with correlational significance measure   p<0.05. For the diet-induced dataset 0.712

and for the pharmacologically-induced dataset 0.791 was identified as correlation

coefficient cut-off. Based on a greedy approach, Louvain community detecting

algorithm [47] was used to cluster the genes based on expression pattern between the

different conditions. Clustering was repeated 100 times. Minimal number of genes per

cluster was set to 50. Gene set enrichment analysis (GSEA) was performed on all

gene-clusters using the following knowledge-bases: Hallmark, Reactome, GO, KEGG

and DO. ClusterProfiler package [48] was used for all GSEAs using default options. The

prior mechanisms associated with the Co-Cena clusters were manually selected from

the GSEA results based on prior knowledge.

Thin layer chromatography

Total lipids were extracted as described by Bligh and Dyer [49]. Livers were

homogenized in ice cold H_2O (50mg wet weight/ml) in a Precellys homogenizer

(Peqlab Biotechnology, Germany). 3 ml of chloroform/methanol 1:2 (v:v) were added

to 800 µl homogenate and vortexed. 1 ml of chloroform was added to the mixture and

vortexed prior to addition of 1 ml H_2O and thoroughly vortexed. Mixture was centrifuged

at 1000 g for 5 min at RT and the lower solvent phase was recovered. Same volumes

of the solvent phase were evaporated under nitrogen and lipids were resuspended in

100 µl of chlorophorm/methanol 1:1 (v:v) (Merck). Lipid extracts corresponding to 1 mg

wet liver weight were applied onto HPTLC silica gel 60 plates (10 X 20 cm: Merck) and

plates were developed in *n*-hexane/diethylether/acetic acid 70:30:5 (v/v/v) (Merck,

Roth) in a developing chamber (CAMAG, Switzerland). Dried plates were soaked in

charring solution (copper sulfate ($CuSO_4$) 10% and phosphoric acid (H_2PO_4) 8%

(Roth)) and heated to 180 °C for 5-10 min for lipid visualization.

Lipid mass spectrometry

Livers were homogenized in ddH_2O at a concentration of 20 mg (wet weight)/ml using

a Precellys homogenizer (Peqlab Biotechnolog, Germany). For lipid extraction, 50 µl

of the homogenate were added to 500 µl of extraction mix ($CHCl_3$/MeOH 1/5 containing

internal standards: 210 pmol PE(31:1), 396 pmol PC(31:1), 98 pmol PS(31:1), 84 pmol

PI(34:0) , 56 pmol PA(31:1), 51 pmol PG (28:0), 28 pmol CL(56:0), 39 pmol LPA (17:0),

35 pmol LPC(17:1), 38 pmol LPE (17:0), 32 pmol Cer(17:0), 99 pmol SM(17:0), 55

pmol GlcCer(12:0), 14 pmol GM3 (18:0-D3), 359 pmol TG(47:1), 111 pmol CE(17:1),

64 pmol DG(31:1), 103 pmol MG(17:1), 724 pmol Chol(d6), 45 pmol Car(15:0)) were

added and the sample sonicated for 2 min followed by centrifugation at 20000 g for 2

min. The supernatant was collected into a new tube and 200 µl chloroform and 800 µl

1% AcOH in water were added, the sample briefly shaken and centrifuged for 2 min at

20000 g. The upper aqueous phase was removed and the entire lower phase

transferred into a new tube and evaporated in the speed vac (45°C, 10 min). Spray

buffer (500 µl of 8/5/1 2-propanol/MeOH/water, 10 mM ammonium acetate) was

added, the sample sonicated for 5 min and infused at 10 µl/min into a Thermo Q

Exactive Plus spectrometer equipped with the HESI II ion source for shotgun

lipidomics. MS1 spectra (resolution 280000) were recorded in 100 m/z windows from

250 – 1200 m/z (pos.) and 200 – 1700 m/z (neg.) followed by recording MS/MS spectra

(res. 70000) by data independent acquisition in 1 m/z windows from 200 – 1200 (pos.)

and 200 – 1700 (neg.) m/z. Raw files were converted to .mzml files and imported into

and analysed by LipidXplorer software using custom mfql files to identify sample lipids

and internal standards. For further data processing, absolute amounts were calculated

using the internal standard intensities followed by calculation of mol% of the identified

lipids.

Tandem affinity purification of tagged Creld2

HEK293 cells were electroporated with plasmid DNA pcDNA3.1/Zeo(+) (Addgene)

containing only the Strep-Flag (SF)-tag (mock), N-terminally tagged Creld2 (FS-C2)

where the tag was integrated after the signal peptide or C-terminally tagged Creld2

(C2-SF). Gene blocks were used to clone the constructs (see Table S10). Primer used

for cloning:

NheI-Kozak-mC2-SF-tag fw 5'-CTAGCTAGCGCCACCATGCACCTGCTGCTTGCA-

3', 5'-Creld2-KpnI TATGGTACCTCACAAATCCTCACGGGAGGG-3',

KpnI-Flag rev 5'-TAGGGTACCTCACTTGTCGTCGTC-3',

NheI-SF-tag fw 5'-CTAGCTAGCATGGGTGGAGGTTCTGGA-3',

KpnI-SF-tag rev 5'-GGAGCTCTGGATGGTACCTCACTTGTC-3'.

Plasmids comprised a zeocin resistance cassette for selection. Cells transiently

expressing C2-SF were harvested 72 h post electroporation for tandem-affinity-

purification (TAP). For the generation of stably expressing cell lines plasmid DNA was

linearized prior to electroporation and selected for stable expression by Zeocin (200

µg/ml) resistance for 4 weeks with validation of construct expression via

immunoblotting against Creld2 and Flag. For TAP cells were incubated on ice in freshly

prepared, ice cold TAP-lysis buffer (1x Complete protease inhibitor (Roche), 1x

Phosphate inhibitor cocktail (PIC) I (Sigma-Aldrich), 1x PIC II (Sigma-Aldrich), 0.5%

NP40 in 1x TBS) for 20 min, centrifuged for 10 min at 10000 g at 4°C and supernatant

was recovered. Subsequently, lysates were incubated with Strep-tactin Sepharose

resin (IBA) for 2 h at 4°C on a rotation wheel. After incubation lysates were transferred

onto Micro Bio-Spin columns (0.8 ml, BioRad), washed 3 times with TAP-wash buffer

(1x PIC I, 1x PIC II, 0.1% NP40 in 1x TBS) and incubated with TAP-elution buffer (50

µM Desthiobiotin (IBA) in 1x TBS) at 4°C for 10 min prior to elution by centrifugation at

100 g for 10 sec. Eluates were incubated with anti-Flag M2 resin (Sigma-Aldrich) for 2

h at 4°C on a rotation wheel, washed once with TAP-wash buffer, twice with TBS and

eluted by incubating samples with Flag elution buffer (200 µg/ml Flag peptide (Sigma-

Aldrich) in 1x TBS) for 10 min following centrifugation for 10 sec at 2000 g. TAPs were

performed in triplicates from cells harvested on different days.

<u>Processing of TAP proteins for mass spectrometry and analysis:</u>

Eluates were reduced with 10 mM Dithiothreitol (DTT) for 30 min at 56 °C followed by

alkylation with 55 mM Chloroacetamide (CAA) for 30 min at RT in the dark.

Subsequently, samples were boiled in laemmli buffer (1 x final concentration 2% SDS,

2 µM DTT, 5% (v/v) Glycerol, 50 µM Tris-HCL (pH 6.8, 0.01% (w/v) Bromophenol blue)

at 95 °C for 10 min and run for approx. 1 cm in a 10% SDS-PAGE gel to separate

purified proteins from the Flag peptide used for elution. Gels were fixed in fixation buffer

(45 % H_2O, 45 % MeOH, 10 % Acetic acid) for 1 h at RT and stained (fixation buffer,

0.05 % Coomassie-G250, filtered) for 1 h at RT followed by a first destaining in fixation

buffer for 1 h prior to destaining O/N. Protein lanes were separated, cut into small

pieces, washed twice with MS-wash buffer (50 mM Ammonium bicarbonate (ABC), 50

% Acetonitrile (ACN)) for 20 min, dehydrated with ACN for 10 min and dried in a speed

vac for 20 min. Afterwards, samples were washed with 50 mM ABC for 15 min at RT

and dehydration was repeated with speed vacuuming for 30 min. For in-gel-digest of

proteins, gel pieces were soaked in digest solution (0,009 µg/µl Trypsin, 0,001 µg/µl

LysC, 45 mM ABC) for 30 min at 4 °C, covered with 50 mM ABC and digested O/N at

37 °C. Supernatants were recovered, gel pieces incubated in extraction buffer (30 %

ACN, 3 % Trifluoroacetic acid (TFA)) for 20 min at RT, supernatants were recovered

and proteins were extracted for another time from gel pieces by incubation in 100 %

ACN for 20 min at RT with recovery of supernatants. The recovered supernatants of

individual samples were pooled, organic solvents were evaporated in a speed vac,

samples were acidified with Formic acid (1 % final concentration), stage tipped and

subjected to mass spectrometry.

<u>TAP mass spectrometry</u>

Raw mass spectrometry data files were analyzed using MaxQuant software (version

1.6.0.16). Further analysis of quantitated proteins was done with Perseus software

(version 1.5.5.3). Data was cleaned by filtering out of reverse proteins, proteins only

identified by site and contaminants, and filtered for valid proteins label-free

quantification (LFQ) values identified in at least 2 technical replicates in minimum 1

condition. Further analysis of data was done using R software. Missing LFQ values

were imputed using the DEP package by firstly imputing of missing not at random

(MNAR) values with 0, followed by a screen for falsely categorized MNAR values and

re-imputation of missing at random (MAR) values using the k-nearest neighbor (knn)

algorithm. For statistical analysis of differentially enriched (DE) proteins two-tailed t-

test with unequal variance was applied to conditions containing Creld2 protein versus

the respective mock control (acute or stable). Proteins with fold change > 0 (Creld2

containing conditions versus mock control) and p-value < 0.1 were considered

differentially enriched.

Patients and ethics

The study protocol conformed to the revised Declaration of Helsinki (Edinburgh, 2000)

and was approved by the local Institutional Review Board (Ethik-Kommission am

Universitätsklinikum Essen; file number 09-4252). All patients provided written

informed consent for participation in the study before recruitment. Liver tissue and

serum were collected from morbidly obese patients undergoing bariatric surgery. All

enrolled patients underwent physical and ultrasound examinations, and a complete set

of laboratory studies. Subjects reporting excessive alcohol consumption (>20 g/day for

men or >10 g/day for women) and those with other known causes of secondary fatty

liver disease (e.g., viral hepatitis, metabolic liver disease, toxic liver disease) were

excluded from the study. Histological evaluation of NAFLD and classification as NAFL

or NASH were performed by two experienced pathologists according to the method of

Bedossa et al. (SAF score [32]).

CRELD2 ELISA

920 Serum CRELD2 levels were measured using a human CRELD2 Elisa kit (Ray Biotech)

921 according to the manufacturers' instructions.

Immunoblotting

Human tissue samples: Liver tissue was directly lysed for 30 min on ice with RIPA

Lysis and Extraction Buffer (Thermo Scientific) containing protease inhibitor cocktail

and phosphostop (Roche). After centrifugation at 13 000 g for 15 min at 4 °C, protein

concentration in the supernatant was measured using Bradford's reagent (Bio-Rad).

Mouse tissue samples: Tissue was snap frozen in liquid N_2 and stored at -80 °C until

usage. Tissue was homogenized in RIPA buffer containing PIC I and PIC II (Sigma-

Aldrich) and Complete protease inhibitor (Roche) using a Precellys homogenizer and

lysed for 30 min on ice. 10-20 µg of total protein were separated by SDS-PAGE and

transferred onto a PVDF membrane (Immobilon-P transfer membranes 0.45 µm,

Merck) via semi-dry blotting (Trans-Blot Turbo Transfer System, Bio-Rad). If not

otherwise mentioned, membranes were incubated with antibodies diluted in TBST

(0.1% Tween20) over night at 4°C on a rocker with the particular antibodies (see Table

S11). Protein band intensities were acquired using ImageJ2. Proteins of one

membrane were normalized to Actin and set relative to a wildtype control located on

the membrane.

Statistical analysis and reproducibility

Data are shown as mean with individual values per mouse represented as circles,

unless stated otherwise. Statistical significance was analysed with R using unpaired

two-tailed t-tests, one-way and two-way ANOVA as indicated in the figure legends. The

n value represents biological replicates. Significance was considered at $P < 0.05$.

Experiments were repeated to ensure reproducibility of the observations. Equal

variance was assumed for cell-counting experiments. No statistical methods were used

to predetermine sample size.

Data availability

Gene expression data are currently being deposited in the GEO database. Lipid mass

spectrometry   data   are   deposited   in   a   Github   repository

https://github.com/maccabaeus/Creld2-lipid-mass-spectrometry.git). The data that

support the findings of this study are available from the corresponding author upon

reasonable request.

Acknowledgements

We thank Prof. Michael Hoch for his long-standing support of this project. We thank

Thomas D. Rutkowski for feedback on the manuscript. We thank Cornelia Cygon and

Melanie Thielisch for technical support, and Dr. Joachim Degen for help with the

generation of *Creld2^eGFP/eGFP* mice. We would like to thank Prof. Margarete Odenthal

(Institute for Pathology, University Hospital Cologne), Prof. Hideo A. Baba und Martin

Schlattjan (Institute for Pathology, University Hospital Essen), and Prof. Johannes

Haybäck (Institute for Pathology, University Hospital Magdeburg) for histological

preparation and assessments for the validation cohort. We also thank Prof.

Niedergethmann (Department for General- and Visceral Surgery, Alfried Krupp

Hospital, Essen, Germany) and Prof. Hasenberg (Helios Hospital Niederberg) for

sample collection of the validation cohort. AC was funded by the DFG CA267/14-1.

EM and JLS were funded by the DFG under Germany's Excellence Strategy EXC2151-

390873048. EM is supported by the Daimler and Benz Foundation. This work was

funded by the Fritz Thyssen foundation (to EM, Az.10.18.2.029MN).

Competing interests

The authors declare no competing interests

Contributions

EM and PK conceived the project. PK, EM, AF, LB, FB performed experiments. PK,

EM, NB, AF analyzed data. EM, PK, and RB supervised experiments and data

analysis. TU and JLS provided help with RNA-seq experiments and the script for

CoCena analyses. CT helped with lipidomic analyses. JPS and AC assisted in

interpretation of human results. EM and PK wrote the manuscript.

References

1.   Rupp, P. A. *et al.* Identification, genomic organization and mRNA expression of CRELD1, the founding member of a unique family of matricellular proteins. *Gene* **293**, 47–57 (2002).

2.   D'Alessandro, M. *et al.* CRELD1 is an evolutionarily-conserved maturational enhancer of ionotropic acetylcholine receptors. *Elife* **7**, (2018).

3.   Oh-hashi, K., Kunieda, R., Hirata, Y. & Kiuchi, K. Biosynthesis and secretion of mouse cysteine-rich with EGF-like domains 2. *FEBS Lett.* **585**, 2481–2487 (2011).

4.   Mass, E., Wachten, D., Aschenbrenner, A. C., Voelzmann, A. & Hoch, M. Murine Creld1 controls cardiac development through activation of calcineurin/NFATc1 signaling. *Dev. Cell* **28**, (2014).

5.   Kim, Y. *et al.* Elevated urinary CRELD2 is associated with endoplasmic reticulum stress–mediated kidney disease. *JCI Insight* **2**, (2017).

6.   Chen, M.-F. *et al.* Synovial fluid interleukin-16, interleukin-18, and CRELD2 as novel biomarkers of prosthetic joint infections. *Bone Joint Res.* **8**, 179–188 (2019).

7.   Oh-hashi, K. *et al.* CRELD2 is a novel endoplasmic reticulum stress-inducible gene. *Biochem. Biophys. Res. Commun.* **387**, 504–510 (2009).

8.   Oh-hashi, K. *et al.* Role of an ER stress response element in regulating the bidirectional promoter of the mouse CRELD2 - ALG12 gene pair. *BMC Genomics* **11**, 664 (2010).

9.   Walter, P. & Ron, D. The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation. *Science (80-.).* **334**, 1081–1086 (2011).

10.   Song, M. J. & Malhi, H. The unfolded protein response and hepatic lipid metabolism in non alcoholic fatty liver disease. *Pharmacol. Ther.* 107401

(2019). doi:10.1016/j.pharmthera.2019.107401

11.   Fu, S. *et al.* Aberrant lipid metabolism disrupts calcium homeostasis causing

liver endoplasmic reticulum stress in obesity. *Nature* **473**, 528–31 (2011).

12.   Ozcan, U. *et al.* Endoplasmic Reticulum Stress Links Obesity, Insulin Action,

and Type 2 Diabetes. *Science (80-.).* **306**, 457–461 (2004).

13.   Ozcan, U. *et al.* Chemical chaperones reduce ER stress and restore glucose

homeostasis in a mouse model of type 2 diabetes. *Science* **313**, 1137–40

(2006).

14.   Kammoun, H. L. *et al.* GRP78 expression inhibits insulin and ER stress-

induced SREBP-1c activation and reduces hepatic steatosis in mice. *J. Clin.*

Invest. **119**, 1201–15 (2009).

15.   Rutkowski, D. T. *et al.* UPR Pathways Combine to Prevent Hepatic Steatosis

Caused by ER Stress-Mediated Suppression of Transcriptional Master

Regulators. *Dev. Cell* **15**, 829–840 (2008).

16.   Yamamoto, K. *et al.* Induction of liver steatosis and lipid droplet formation in

ATF6alpha-knockout mice burdened with pharmacological endoplasmic

reticulum stress. *Mol. Biol. Cell* **21**, 2975–86 (2010).

17.   DeZwaan-McCabe, D. *et al.* ER Stress Inhibits Liver Fatty Acid Oxidation while

Unmitigated Stress Leads to Anorexia-Induced Lipolysis and Both Liver and

Kidney Steatosis. *Cell Rep.* **19**, 1794–1806 (2017).

18.   Oh-Hashi, K., Fujimura, K., Norisada, J. & Hirata, Y. Expression analysis and

functional characterization of the mouse cysteine-rich with EGF-like domains 2.

Sci. Rep. **8**, 12236 (2018).

19.   Soontornniyomkij, V. *et al.* Age and High-Fat Diet Effects on Glutamine

Synthetase Immunoreactivity in Liver and Hippocampus and Recognition

Memory in Mice. *Curr. Aging Sci.* **9**, 301–309 (2016).

20.   Birkenfeld, A. L. & Shulman, G. I. Nonalcoholic fatty liver disease, hepatic

1035   insulin resistance, and type 2 diabetes. *Hepatology* **59**, 713–23 (2014).

1036   21.   Gruben, N., Shiri-Sverdlov, R., Koonen, D. P. Y. & Hofker, M. H. Nonalcoholic

1037   fatty liver disease: A main driver of insulin resistance or a dangerous liaison?

1038   *Biochim. Biophys. Acta - Mol. Basis Dis.* **1842**, 2329–2343 (2014).

1039   22.   Adachi, Y. *et al.* ATF6 Is a Transcription Factor Specializing in the Regulation

1040   of Quality Control Proteins in the Endoplasmic Reticulum. *Cell Struct. Funct.*

1041   **33**, 75–89 (2008).

1042   23.   Lefere, S. & Tacke, F. Macrophages in obesity and non-alcoholic fatty liver

1043   disease: Crosstalk with metabolism. *JHEP Reports* **1**, 30–43 (2019).

1044   24.   Wu, J. *et al.* ATF6alpha optimizes long-term endoplasmic reticulum function to

1045   protect cells from chronic stress. *Dev. Cell* **13**, 351–64 (2007).

1046   25.   Kuipers, E. J. *et al.* REVIEWS IN BASIC AND CLINICAL

1047   GASTROENTEROLOGY AND HEPATOLOGY Bioactive Lipid Species and

1048   Metabolic Pathways in Progression and Resolution of Nonalcoholic

1049   Steatohepatitis. (2018). doi:10.1053/j.gastro.2018.06.031

1050   26.   Musso, G., Cassader, M., Paschetta, E. & Gambino, R. Bioactive Lipid Species

1051   and Metabolic Pathways in Progression and Resolution of Nonalcoholic

1052   Steatohepatitis. *Gastroenterology* **155**, 282-302.e8 (2018).

1053   27.   Gloeckner, C. J., Boldt, K., Schumacher, A. & Ueffing, M. Tandem affinity

1054   purification of protein complexes from mammalian cells by the Strep/FLAG

1055   (SF)-TAP tag. *Methods Mol. Biol.* **564**, 359–72 (2009).

1056   28.   Hartley, C. L. *et al.* Armet/Manf and Creld2 are components of a specialized

1057   ER stress response provoked by inappropriate formation of disulphide bonds:

1058   implications for genetic skeletal diseases. *Hum. Mol. Genet.* **22**, 5262–75

1059   (2013).

1060   29.   Horna-Terrón, E., Pradilla-Dieste, A., Sánchez-de-Diego, C. & Osada, J.

1061   TXNDC5, a newly discovered disulfide isomerase with a key role in cell

1062   physiology and pathology. *Int. J. Mol. Sci.* **15**, 23501–18 (2014).

1063   30.   Board, P. G. & Menon, D. Glutathione transferases, regulators of cellular

1064   metabolism and physiology. *Biochim. Biophys. Acta - Gen. Subj.* **1830**, 3267–

1065   3288 (2013).

1066   31.   Zhang, Z. *et al.* Redox signaling and unfolded protein response coordinate cell

1067   fate decisions under ER stress. *Redox Biol.* (2018).

1068   doi:10.1016/J.REDOX.2018.11.005

1069   32.   Bedossa, P. *et al.* Histopathological algorithm and scoring system for

1070   evaluation of liver lesions in morbidly obese patients. *Hepatology* **56**, 1751–

1071   1759 (2012).

1072   33.   Han, J. & Kaufman, R. J. The role of ER stress in lipid metabolism and

1073   lipotoxicity. *Journal of Lipid Research* **57**, 1329–1338 (2016).

1074   34.   Longato, L., Tong, M., Wands, J. R. & de la Monte, S. M. High fat diet induced

1075   hepatic steatosis and insulin resistance: Role of dysregulated ceramide

1076   metabolism. *Hepatol. Res.* **42**, 412–27 (2012).

1077   35.   Kurek, K. *et al.* Inhibition of ceramide de novo synthesis reduces liver lipid

1078   accumulation in rats with nonalcoholic fatty liver disease. *Liver Int.* **34**, 1074–

1079   1083 (2014).

1080   36.   Abdullahi, A., Stanojcic, M., Parousis, A., Patsouris, D. & Jeschke, M. G.

1081   Modeling Acute ER Stress in Vivo and in Vitro. *SHOCK* **47**, 506–513 (2017).

1082   37.   Ballestri, S. *et al.* NAFLD as a Sexual Dimorphic Disease: Role of Gender and

1083   Reproductive Status in the Development and Progression of Nonalcoholic Fatty

1084   Liver Disease and Inherent Cardiovascular Risk. *Advances in Therapy* **34**,

1085   1291–1326 (2017).

1086   38.   Lonardo, A. & Suzuki, A. Nonalcoholic fatty liver disease: does sex matter?

1087   *HepatoBiliary Surg. Nutr.* **8**, 164–166 (2019).

1088   39.   Hodeify, R. *et al.* Gender differences control the susceptibility to ER stress-

1089   induced acute kidney injury. *Am. J. Physiol. - Ren. Physiol.* **304**, (2013).

1090   40.   Liu, G.-M., Zeng, H.-D., Zhang, C.-Y. & Xu, J.-W. Key genes associated with

1091   diabetes mellitus and hepatocellular carcinoma. *Pathol. - Res. Pract.* 152510

1092   (2019). doi:10.1016/j.prp.2019.152510

1093   41.   Matthews, D. R. *et al.* Homeostasis model assessment: insulin resistance and

1094   beta-cell function from fasting plasma glucose and insulin concentrations in

1095   man. *Diabetologia* **28**, 412–9 (1985).

1096   42.   Picelli, S. *et al.* Smart-seq2 for sensitive full-length transcriptome profiling in

1097   single cells. *Nat Methods* **10**, 1096–1098 (2013).

1098   43.   Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic

1099   RNA-seq quantification. *Nat. Biotechnol.* **34**, 525–527 (2016).

1100   44.   Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and

1101   dispersion for RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014).

1102   45.   Ritchie, M. E. *et al.* Limma powers differential expression analyses for RNA-

1103   sequencing and microarray studies. *Nucleic Acids Res.* **43**, e47 (2015).

1104   46.   Leek, J. *et al.* sva: Surrogate Variable Analysis. R package version 3.34.0.

1105   (2019).

1106   47.   Blondel, V. D., Guillaume, J. L., Lambiotte, R. & Lefebvre, E. Fast unfolding of

1107   communities in large networks. *J. Stat. Mech. Theory Exp.* **2008**, (2008).

1108   48.   Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for

1109   comparing biological themes among gene clusters. *OMICS* **16**, 284–287

1110   (2012).

1111   49.   BLIGH, E. G. & DYER, W. J. A rapid method of total lipid extraction and

1112   purification. *Can. J. Biochem. Physiol.* **37**, 911–917 (1959).

1113

Kern et al. Fig. 1

Figure 1: *Creld2^{eGFP/eGFP}* males develop liver steatosis with progressing age. (A) Animals born from *Creld2^{WT/GFP}* x *Creld2^{WT/GFP}* matings. **(B)** Body weight of males (1 month: n = 5-7; 2 months: n = 44-50; 12-15 months: n = 18-23) **(C)** Liver weight of males (2 months: n = 5; 12-15 months: n = 11-14). Error bars represent ± SD. Unpaired two-tailed t-test. **(D)** Histological analysis of 1-year-old male livers by hemalaun and eosin (HE) (top), Oil-red-O (middle) and anti-GS (Glutamine synthetase) antibody (bottom). Arrowheads indicate ectopic GS expression. Scale bars of the overview: 100 µm. Scale bars of the insets: 10 µm. **(E)** Thin layer chromatography of total lipid extracts from 1-year-old animals (♂; n = 4, ♀; n = 3-5). Circles represent individual mice, grey lines are means of control littermates. Unpaired two-tailed t-test. **(F-G)** Glucose tolerance test (GTT, n = 9-10) (F) and insulin tolerance test (ITT, n = 8-9) of 1-year-old male mice (G). Error bars represent ± SD. Unpaired two-tailed t-test. **(H)** Ratio of phosphorylated Akt (p-Akt)/Akt expression in livers after 15 min of insulin administration in 1-year-old male mice (n = 4-5). Circles represent individual mice. Unpaired two-tailed t-test.

Kern et al. Fig. 2

Figure 2: 1-year-old *Creld2eGFP/eGFP* male mice display downregulation of key lipid metabolism genes and increased ER stress marker expression. (A, B, D) qRT-PCR analysis of male livers (n = 3-5). Gene expression is displayed as relative value. Unpaired two-tailed t-test. * p < 0.05, ** p < 0.01. **(C)** Protein expression in livers of male mice as assessed by Western blot quantification (n = 17-19). For Perk and eIF2α ratios of phosphorylated (P-Perk and P-eIF2α) and unphosphorylated protein abundance are displayed.

Figure 3: *Creld2eGFP/eGFP* mouse embryonic fibroblasts (MEFs) show reduced survival after ER stress. (A) Relative MEFs cell numbers determined by crystal violet assay after induction of chronic ER stress with various Tm (tunicamycin; up to 3 days; n = 6-16) or Tg (thapsigargin; up to 2 days; n = 13-16) doses. **(B)** Relative MEFs cell numbers determined by crystal violet assay after induction of ER stress by 1 µM Tg for up to 8 hours followed by a 5-day culture period without Tg (n = 5-8). Error bars in (A) and (B) represent ± SEM. **(C-I)** MEFs were cultured with Tg for 2 hours to induce ER stress followed by removal of Tg (hours indicate duration of experiment) to analyze the recovery capability of *Creld2eGFP/eGFP* cells. **(C)** qRT-PCR of the general ER stress markers *Grp78* (n = 8-10), *Grp94* (n = 3) and *Chop* (n = 8-10). **(D)** Protein expression of Grp78 (n = 7-8) and Chop (n = 3-4) assessed by Western blot. Protein expression is normalized to control at 0h. **(E)** Analysis of ATF6α-pathway components expression via qRT-PCR of *Edem1* (n = 8-10), *Derl3* (n = 8-10), *eGFP* (n = 5) and *Creld2* (n = 10). **(F)** Protein expression of Creld2 (n = 10). **(G)** qRT-PCR of *Perk* and *Gadd34* (n = 8-10). **(H)** Ratios of phosphorylated (P-Perk and P-eIF2α) and unphosphorylated Perk and P-eIF2α assessed by Western blot quantification (n = 5). **(I)** qRT-PCR analysis of *Ire1a* and s*Xbp1* (n = 8-10). Error bars in (D, F, H) represent ± SD. Gene expression (C, E, G, I) is displayed as relative value. * p < 0.05; ** p < 0.01; *** p < 0.001, **** p < 0.0001.

Figure 4: Tissue and molecular response of *Creld2^eGFP/eGFP* mice to high-fat diet. (A) Experimental setup. **(B)** Body weight of male mice fed with CD (control diet; n = 13-14) and HFD (high-fat diet; n = 12-31) for 12 weeks, or HFD for 8 weeks following CD for 4 weeks (n = 14-19). **(C)** Analysis of insulin resistance induction by HFD via HOMA-IR (homeostatic model assessment of insulin resistance, CD start: n = 22-29; CD 8 weeks: n = 7-10; HDF 8 weeks: n = 17-20). One-way ANOVA with Turkey post-hoc test. **(D)** Liver (n = 12-19) and eWat (epididymal white adipose tissue, n = 9-14) weights of mice after 12 weeks of diet. **(E)** Lipid mass spectrometry of livers (n = 5). DAG: Diacylglycerol. TAG: Triacylglycerol. Circles represent individual mice. One-way ANOVA. **(F)** Co-expression network analysis (CoCena) performed on RNA-seq data of livers (n = 5 per condition). Numbers indicate genes belonging to a module. Colours represent cluster names: midnightblue: 703 genes, cyan: 268 genes, blue: 403 genes, orange: 342 genes, purple: 833 genes, royalblue: 63 genes, black: 126 genes. GFC: group fold change. **(G)** Heatmap representation of selected genes from (F), values are displayed as z scores. **(H)** Lipid mass spectrometry analysis for ceramides. Circles represent individual mice. One-way ANOVA with Turkey post-hoc test. **(I)** Western blot analysis for cleaved Caspase 3 (n = 5). Circles represent individual mice. Unpaired two-tailed t-test. **(J)** Western blot analysis for UPR components (n = 5). For Perk and eIF2α, ratios of phosphorylated (P-Perk and P-eIF2α) and unphosphorylated protein abundance are displayed. Circles represent individual mice. * p < 0.05; ** p < 0.01; *** p < 0.001, **** p < 0.0001.

Kern et al. Fig. 5

Figure 5: Tissue and molecular response of *Creld2^eGFP/eGFP* mice to pharmacological ER stress induction. (A) Experimental setup. **(B)** Quantification of liver PAS stainings and mass spectrometrical assessment of liver lipids. Circles represent individual mice. One-way ANOVA with Turkey post-hoc test. **(C)** Elevated lipid levels are mainly attributable to accumulated DAG (diacylglicerides), TAG (triacylglicerides) and CE (cholesteryl esters). Circles represent individual mice. One-way ANOVA with Turkey post-hoc test. **(D)** Co-expression network analysis (CoCena) performed on RNA-seq data of livers (n = 5 per condition). Numbers indicate genes belonging to a module. Colours represent cluster names: skyblue: 273 genes, darkorange: 1257 genes, antiquewhite: 52 genes, brown: 713 genes, mediumorchide: 298 genes, royalblue: 1044 genes, honeydew: 254 genes. GFC: group fold change. **(E)** Heatmap representation of selected genes from (D), values are displayed as z scores. **(F)** Western blot analysis for UPR components (n = 5). For Perk and eIF2α, ratios of phosphorylated (P-Perk and P-eIF2α) and unphosphorylated protein abundance are displayed. Circles represent individual mice. One-way ANOVA with Turkey post-hoc test. * p < 0.05; ** p < 0.01; *** p < 0.001, **** p < 0.0001.

Figure 6: Creld2 interacts with proteins involved in protein folding, response to ER stress and detoxification. **(A)** Schematic representation of constructs and expression conditions used for tandem-affinity-purification of tagged mouse Creld2. **(B)** Workflow chart for analysis of mass spectrometry data. knn: k-nearest neighbour; MAR: missing at random; MNAR: missing not at random. **(C)** Enriched Creld2 interaction partners across the different expression conditions. **(D)** Top three enriched GO terms resulting from enrichment analysis of all co-purified proteins.

Kern et al. Fig. 7

Figure 7: Hepatic CRELD2 expression increases in patients with non-alcoholic steatohepatitis. (A) Hepatic gene and protein expression levels of CRELD2 in male (♂) and female (♀) non-alcoholic fatty liver disease (NAFLD) patients (grey circles) with or without NASH (non-alcoholic steatohepatitis) and healthy controls (green circles). Cohort is comprised of 57 patients. Circles represent individual patients. Unpaired two-tailed t-test. **(B)** Analysis of CRELD2 serum concertation in male (♂) and female (♀) patients plotted against the Steatosis Activity and Fibrosis (SAF) score (cohort comprised of 40 patients). Linear regression model. Circles represent individual patients. **(C)** Summarizing schematic of Creld2 functionality. PDI: protein disulfide isomerase; ROS: reactive oxygen species.

Supplemental Figure 1: Generation and phenotypic analysis of the *Creld2eGFP/eGFP* mouse. **(A)** Gene targeting strategy. The complete genetic locus of *Creld2* was replaced by an eGFP reporter via homologous recombination. The targeting vector comprised a neoR cassette flanked by FRT sites for positive ES cell selection. Following recombination, the neoR cassette was excised by FLP-mediated deletion. Primers for ES cell screening (gt2_fw, gt2_rv, neo_fw) and probes used for Southern blotting (5' probe, internal probe) and the resulting fragment lengths (bp) are indicated. **(B)** Tissue expression profile of Creld2 and testing of the anti-Creld2 antibody specificity by immunoblotting. Arrowheads indicate unspecific protein bands. **(C)** Histological analysis of liver and muscle tissue by hemalaun and eosin (HE) and Masson Goldner trichrome (MGT) in young *Creld2eGFP/eGFP* and wildtype mice. Representative for n = 8-10. **(D-E)** Representative PAS (Periodic acid Schiff) and MGT staining of 1-year-old male livers and staining evaluation (n = 11-12). Scale bar represents 100 μm. **(F)** Representative immunoblots of liver lysates from 1-year-old male mice. Refers to main Figure 2C.

Supplemental Figure 2: Gene regulation and immune response in 1-year-old mice. (A-C) qRT-PCR analysis of 1-year-old female livers (n = 2-8). Gene expression is displayed as relative value. Unpaired two-tailed t-test. **(D)** Flow cytometry analysis of liver Kupffer cells ($CD45^+CD11b^{low}F4/80^+Tim4^+$) in male mice (n = 3-9). **(E)** qRT-PCR analysis of pro-inflammatory cytokines *Tnfa*, *Il1b* and *Il6* in bone-marrow derived macrophages after LPS treatment isolated from males (n = 3-4). Error bars represent ± SD.

Supplemental Figure 3: *Creld2^{eGFP/eGFP}* **MEFs show differential responses to chronic and acute ER stress. (A-I)** UPR analysis of MEFs during chronic ER stress induced by either Tg (Thapsigargin) or Tm (Tunicamycin) for up to 48 h or 72 h, respectively (n = 3). **(A, B)** Gene (A) and protein expression analysis (B) of major ER stress makers during chronic ER stress. **(C-D)** Analysis of Perk pathway components via qRT-PCR (C) and Western blot (D). **(E)** Gene expression of *Ire1a* and *sXbp1* during chronic ER stress. **(F-H)** Analysis of Atf6 and downstream targets via qRT-PCR (F, H) and Western blot (G). **(I)** Representative immunoblots of MEFs during chronic ER stress. **(J)** Determination of the successful UPR induction by Tg (1 µM, up to 8 h) for the establishment of an *in vitro* ER stress recovery model shows upregulation of most of the monitored UPR components already after 2 h of Tg treatment (n = 2-4). **(K)** Representative immunoblots of MEFs during ER stress recovery. M: marker/ladder. Refers to main figure 3D, F, H.

Supplemental Figure 4: Diet-induced hepatosteatosis and analysis of liver damage. (A-F) Representative histological analyses of livers from mice on different diets by (A) ORO (Oil-red-O), (C) PAS (Periodic Acid Schiff) and (E) MGT (Masson Goldner trichrome) staining and their corresponding quantification (B, D, F). **(G)** Determination of liver damage by serum alanine aminotransferase (ALT) concentration. Circles represent individual mice (B, D, F). Scale bars represent 100 μm. **(H)** Principle component analysis of liver RNA-seq data shown in Figure 4. **(I)** Representative immunoblots of liver protein lysates on different diets. Refers to main Figure 4J.

Supplemental Figure 5: Pharmacologically induced hepatosteatosis and analysis of liver damage. (A) ORO (Oil-red-O) staining of livers from ER stress induced mice (Ctrl: Sucrose control; Tg: Thapsigargin; Tm: Tunicamycin) and **(B)** ORO staining quantification. **(C)** PAS (Periodic Acid Schiff) staining. For PAS signal intensity quantification see Figure 5B. **(D, E)** MGT (Masson Goldner trichrome) staining and quantification. Circles represent individual mice (B, E). Scale bars represent 100 μm. **(F)** Principle component analysis of liver RNA-seq data shown in Figure 5. **(G)** Representative immunoblots of liver protein lysates injected with sucrose control (Ctrl), Tg (thapsigargin) or Tm (tunicamysin). Refers to main Figure 5F.